ArticleChemical science2019
Enabling synthesis in fragment-based drug discovery by reactivity mapping: photoredox-mediated cross-dehydrogenative heteroarylation of cyclic amines.
Article in Chemical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Developments and challenges in hit progression within fragment-based drug discovery.Nature communications · 2026Review
- Regio- and Stereocontrolled-Synthesis of a Heterocycle Fragment Collection Using Palladium Catalyzed C-H Arylation.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Modular Synthetic Platform for the Elaboration of Fragments in Three Dimensions for Fragment-Based Drug Discovery.Journal of the American Chemical Society · 2025Article
- Emerging trends in the optimization of organic synthesis through high-throughput tools and machine learning.Beilstein journal of organic chemistry · 2025Review
- Discovery of Trypanosoma brucei inhibitors enabled by a unified synthesis of diverse sulfonyl fluorides.Communications chemistry · 2024Article
- Acridine/Lewis Acid Complexes as Powerful Photocatalysts: A Combined Experimental and Mechanistic Study.ACS catalysis · 2024Article
- Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist's toolbox reactions.RSC medicinal chemistry · 2023Article
- Accelerated Chemical Reaction Optimization Using Multi-Task Learning.ACS central science · 2023Article
- A Brief Introduction to Chemical Reaction Optimization.Chemical reviews · 2023Review
- Visible-light-induced dual catalysis forChemical science · 2022Article
- Regioselective C-3-alkylation of quinoxalin-2(1RSC advances · 2022Article
- Technological Innovations in Photochemistry for Organic Synthesis: Flow Chemistry, High-Throughput Experimentation, Scale-up, and Photoelectrochemistry.Chemical reviews · 2022Review
- Switchable, Reagent-Controlled Diastereodivergent Photocatalytic Carbocyclisation of Imine-Derived α-Amino Radicals.Angewandte Chemie (International ed. in English) · 2021Article
- Targeting NRF2 to treat cancer.Seminars in cancer biology · 2021Review
- Gram-Scale Domino Synthesis in Batch and Flow Mode of Azetidinium Salts.The Journal of organic chemistry · 2021Article
- C-H functionalisation tolerant to polar groups could transform fragment-based drug discovery (FBDD).Chemical science · 2021Article
- Discovery of a photochemical cascade process by flow-based interception of isomerising alkenes.Chemical science · 2021Article
- Rapid Optimization of Photoredox Reactions for Continuous-Flow Systems Using Microscale Batch Technology.ACS central science · 2021Article
- Advancement in Organic Synthesis through High Throughput Experimentation.Chemistry methods : new approaches to solving problems in chemistry · 2021Article
- α-C-H/N-H Annulation of Alicyclic Amines via Transient Imines: Preparation of Polycyclic Lactams.Organic letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In fragment-based drug discovery (FBDD), a weakly binding fragment hit is elaborated into a potent ligand by bespoke functionalization along specific directions (growth vectors) from the fragment core in order to complement the 3D structure of the target protein. This structure-based design approach can present significant synthetic challenges, as growth vectors often originate on sp
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.